In this issue
Data presented at the European Society for Medical Oncology (ESMO) Congress 2025 signal a potential shift in the management of early-stage human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer.
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


We’ve noticed you’re accessing
from North/South America.
from North/South America.